Assessment of Geriatric Evaluations Impact on New AML Guidance

NCT05909501 · Abramson Cancer Center at Penn Medicine

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title

AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

About this study

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility criteria

Inclusion Criteria: * AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy * New diagnosis being considered for new line of treatment * Age ≥ 50 years. * Performance status 0,1, and 2 Exclusion Criteria: * Inability to understand or unable to sign a written informed consent * Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Study design

Enrollment target: 100 participants

Age groups: adult, older_adult

Timeline

Starts: 2023-10-25

Estimated completion: 2026-12-01

Last updated: 2025-08-07

Primary outcomes

• Evaluate physiologic age using baseline measures of physical function, depression, cognition, frailty, and PROs in newly diagnosed AML patients receiving intensive and non-intensive treatment in relation to overall survival at 1 year. (At baseline, 14 days after treatment, 1 month after treatment)
• Evaluate baseline measures of physiologic age in relation to short term mortality (At 30 days and 60 days)
• Evaluate baseline measures of physiologic age in relation to grade 3, 4, and 5 toxicities from treatment (At baseline, 14 days after treatment, 1 month after treatment)

Sponsor

Abramson Cancer Center at Penn Medicine · other

With: Bristol-Myers Squibb

Contacts & investigators

ContactColleen Redlinger · contact · colleen.redlinger@pennmedicine.upenn.edu · 2152209693

ContactCatherine Lai, MD · contact · Catherine.Lai@Pennmedicine.upenn.edu · 2153600561

InvestigatorCatherine Lai, MD · principal_investigator, Abramson Cancer Center at Penn Medicine

All locations (1)

Abramson Cancer Center at University of PennsylvaniaRecruiting

Philadelphia, Pennsylvania, United States

View on ClinicalTrials.gov ↗Find similar trials